Guest:

Dr. Lynn Kirkpatrick Chief Executive Officer, Ensysce Biosciences Inc.

Ticker: $ENSC (NASDAQ)

Website:

https://ensysce.com/

Bio:

Dr. Lynn Kirkpatrick

Chief Executive Officer, Ensysce Biosciences Inc.

Dr. Kirkpatrick has focused her entire career on drug discovery and development. Former Professor of Chemistry and Biochemistry in Canada, she has been active in both the novel drug discovery as well as clinical development of drug candidates throughout her career. She co-founded three start-up companies and successfully brought three novel cancer drug candidates and two other drug candidates in pain and infectious diseases from bench into human clinical trials.

Following the acquisition of the first company she co-founded, ProlX Pharmaceuticals, she became President and CEO of Ensysce Biosciences Inc. and took the company public in 2021. Now Dr. Kirkpatrick is guiding the clinical development of Ensysce’s highly novel pain products, which use compelling chemical approaches to reduce abuse and overdose potential. Dr. Kirkpatrick received her PhD in Medicinal Chemistry from the University of Saskatchewan and completed a post-doctoral fellowship in Pharmacology at Yale University School of Medicine before returning to Canada where she spent 16 years in academia.

She has published extensively in the area of targeted cancer drug discovery and development and holds numerous patents for novel drug candidates.

Company Bio:

Ensysce Biosciences is developing first-in-class and uniquely innovative solutions in oral drug delivery. Our proprietary TAAP™ and MPAR® technologies improve the care and safety of patients by preventing the possibility of both abuse and overdose of prescription drugs. Our mission is to revolutionize the safety and oral delivery of medicines for areas of high unmet need.